The future of new drugs for diabetes management

Keyphrases

• Diabetes Management 100%
• New Drugs 100%
• Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i) 100%
• Type 2 Diabetes Mellitus (T2DM) 75%
• A1 Receptor 50%
• Glucagon-like 50%
• Glucose-lowering Drugs 50%
• Receptor Agonist 50%
• Cardiovascular Outcome Trials 50%
• Cardiorenal Syndrome 50%
• Glycemic Control 25%
• Effective Management 25%
• Comorbidity 25%
• High Cost 25%
• Cardiovascular Safety 25%
• Dipeptidyl peptidase-4 (DPP-4) 25%
• Albuminuria 25%
• Weight Management 25%
• Glomerular Filtration Rate 25%
• Major Adverse Cardiovascular Events 25%
• Nonfatal Myocardial Infarction 25%
• Control Management 25%
• Heart Failure Hospitalization 25%
• Outcome Trials 25%
• Cardiorenal 25%
• Renal Parameters 25%

Medicine and Dentistry

• Diabetes 100%
• Maturity Onset Diabetes of the Young 100%
• Cardiovascular System 100%
• Glucagon-Like Peptide-1 Agonist 66%
• Sodium Glucose Cotransporter 2 Inhibitor 66%
• Nephropathy 66%
• Health Care Cost 33%
• Myocardial Infarction 33%
• Cardiovascular Disease 33%
• Apoplexy 33%
• Glycemic Control 33%
• Dipeptidyl Peptidase-4 Inhibitor 33%
• Glomerular Filtration Rate 33%
• Weight Management 33%
• Congestive Heart Failure 33%
• Albuminuria 33%
• Comorbidity 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Non Insulin Dependent Diabetes Mellitus 100%
• Sodium Glucose Cotransporter 2 Inhibitor 66%
• Glucagon Like Peptide 1 Receptor Agonist 66%
• Kidney Disease 66%
• Heart Infarction 33%
• Dipeptidyl Peptidase IV Inhibitor 33%
• Albuminuria 33%
• Cerebrovascular Accident 33%
• Congestive Heart Failure 33%
• Cardiovascular Disease 33%
• Comorbidity 33%